Search company, investor...


Founded Year



Acq - P2P | Acquired



About Thoratec

Thoratec specializes in therapies to address advanced-stage heart failure. The company's products include the HeartMate II and HeartMate III LVAS (Left Ventricular Assist Systems) and Thoratec VAD (Ventricular Assist Device) with more than 20,000 devices implanted in patients suffering from heart failure. Thoratec also manufactures and distributes the CentriMag and PediMag/PediVAS product lines. Thoratec is headquartered in Pleasanton, California.

Headquarters Location

6035 Stoneridge Drive

Pleasanton, California, 94588,

United States


Missing: Thoratec's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: Thoratec's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Expert Collections containing Thoratec

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Thoratec is included in 1 Expert Collection, including Medical Devices.


Medical Devices

3,383 items

Companies that received PMA from the FDA since 2014. Companies tagged as #FDAPMA

Thoratec Patents

Thoratec has filed 235 patents.

The 3 most popular patent topics include:

  • Cardiac anatomy
  • Cardiac surgery
  • Cardiology
patents chart

Application Date

Grant Date


Related Topics




Pumps, Fluid dynamics, Heart diseases, Cardiology, Vacuum tubes


Application Date


Grant Date



Related Topics

Pumps, Fluid dynamics, Heart diseases, Cardiology, Vacuum tubes



Latest Thoratec News

Cardiopulmonary Bypass System Market Overview 2022 to 2032 | By Minnetronix, Terumo, Eurosets, Thoratec

May 9, 2023

| By Minnetronix, Terumo, Eurosets, Thoratec The global Cardiopulmonary Bypass System market size is estimated to be worth US$ 271 million by 2032, up from US$ 192 million in 2022, at a CAGR of 3.2% over the forecast period. The rising expense of treating severe illnesses like heart disease is likely to drive demand for cardiopulmonary bypass devices. However, the undesirable side effects of bypass procedures are likely to limit their use. Rapid technological improvements, on the other hand, are anticipated to drive industry advancement and present market participants with inventive opportunities. Get a PDF Sample with Latest Market Insights@ Roller cardiopulmonary bypass pumps are predicted to gain in the Cardiopulmonary Bypass System market share due to its benefits. These advantages include lower pricing, simplicity, ease of use, dependability in flow computation, and increased resistance without diminishing flow. Cardiopulmonary Bypass System Infection Market: Drivers and Restraints The rising prevalence of cardiac diseases and the growing older population are the key factors driving the growth of the Cardiopulmonary Bypass System market. Increased healthcare spending and disposable income are propelling the Cardiopulmonary Bypass System market forward. Favourable reimbursement regulations and increased government support from emerging countries have assisted the market spread of the Cardiopulmonary Bypass System. NGO cardiac disease awareness activities are minor market drivers for the Cardiopulmonary Bypass System. New breakthrough technologies and increased product releases for Cardiopulmonary Bypass System have fueled market expansion. On the other hand, the high cost of cardiac surgery, as well as the risk of operation failure, may hinder the growth of the Cardiopulmonary Bypass System market. Cardiopulmonary Bypass System Market: Overview During the forecast period, the rising prevalence of cardiac disorders is expected to generate considerable growth in the worldwide Cardiopulmonary Bypass System market. The need for Cardiopulmonary Bypass Systems has increased as the number of patients undergoing cardiac surgery has increased. These systems are classified according to their product type, mode of operation, and end user. Conventional Cardiopulmonary Bypass System and Cardiopulmonary Bypass System are the two types of Cardiopulmonary Bypass Systems. The traditional Cardiopulmonary Bypass System is likely to dominate in terms of market value. Based on end-user, the Cardiopulmonary Bypass System market is divided into hospitals, ambulatory surgery centres, and cardiac research centres. Hospitals are expected to have the largest market share in terms of value among all end-users. Manufacturing enterprises producing low-cost Cardiopulmonary Bypass Systems may give a potential for market expansion in low-income countries. Cardiopulmonary Bypass System Market: Regional Overview Global Cardiopulmonary Bypass System are classified into seven key regions based on regional presence: North America, Latin America, Western Europe, Eastern Europe, Asia-Pacific excluding Japan, Japan, and the Middle East and Africa. Because of its extensive healthcare infrastructure and favourable reimbursement scenario, North America is the most profitable market for Cardiopulmonary Bypass System. Following North America, the market for Cardiopulmonary Bypass System is followed by Western Europe and Asia-Pacific excluding Japan. Because of the high prevalence of cardiac diseases and the growing geriatric population in the APEJ region, India and China are the major markets for Cardiopulmonary Bypass System. Cardiopulmonary Bypass System Market: Key Players Examples of some of the market participants in Cardiopulmonary Bypass System market identified across the value chain include Sorin Group, Braile Biomedica, Transonic, Spectrum Medical, Minnetronix, Inc., Medtronic plc., MAQUET Holding B.V. & Co. KG. and others. Major market players of Cardiopulmonary Bypass System market are focusing on mergers and acquisitions to retain their market share. We Offer tailor-made Solutions to fit Your Requirements, Request Customization@ Cardiopulmonary Bypass System Market: Segmentation The global Cardiopulmonary Bypass System market is classified on the basis of product type, modality, end user, and region. Based on product type Cardiopulmonary Bypass System market is segmented into following: Conventional Cardiopulmonary Bypass System Standalone Hospitals

Thoratec Frequently Asked Questions (FAQ)

  • When was Thoratec founded?

    Thoratec was founded in 1905.

  • Where is Thoratec's headquarters?

    Thoratec's headquarters is located at 6035 Stoneridge Drive, Pleasanton.

  • What is Thoratec's latest funding round?

    Thoratec's latest funding round is Acq - P2P.

  • Who are the investors of Thoratec?

    Investors of Thoratec include St. Jude Medical.

  • Who are Thoratec's competitors?

    Competitors of Thoratec include Abiomed.

Compare Thoratec to Competitors

Jarvik Heart

Jarvik Heart is a private company that develops miniaturized heart assist devices for the treatment of severe heart failure.

Teleflex Logo

Teleflex (NYSE: TFX) manufactures and markets surgical instruments and devices in the United States and internationally. It offers surgical instruments, appliances, cardiac devices, and other products. Teleflex was formerly known as Hudson Respiratory Care. The company was founded in 1943 and is based in Wayne, Pennsylvania.


ReliantHeart is a provider in mechanical circulatory support therapies for advanced stage heart failure. The company manufactures the HeartAssist5, a next generation ventricular assist device (VAD) which has CE Mark approval for commercial sale in Europe. The HeartAssist5 is an implantable, electric pump designed for use in patients requiring ventricular support due to end stage heart failure and is the world's only remotely monitored VAD.


BiVACOR develops an artificial heart-pumping device designed to take over the complete function of a patient's failing heart. The compact device comprises a magnetically levitated rotor located between opposing pump casings and leverages rotary blood pump technology to provide the required cardiac output. The company was founded in 2008 and is based in Houston, Texas.

Stryker Logo

Stryker (NYSE: SYK) develops, manufactures, and markets specialty surgical and medical products worldwide. It offers orthopedic implants, trauma systems, powered surgical instruments, endoscopic systems, and, patient care and handling equipment. It was founded in 1941 and is based in Kalamazoo, Michigan.

SynCardia Systems

SynCardia Systems is a manufacturer of the Total Artificial Heart. The SynCardia Total Artificial Heart is approved as a bridge to transplant for people suffering from end-stage heart failure affecting both sides of the heart (biventricular failure). Similar to a heart transplant, the SynCardia Total Artificial Heart replaces both failing heart ventricles and the four heart valves, eliminating the symptoms and source of end-stage biventricular failure. Unlike a donor heart, the Total Artificial Heart is immediately available at SynCardia Certified Centers. On September 30th, 2021, SynCardia Systems was acquired by Picard Medical. The terms of the transaction were not disclosed.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.